Ohio State University-ko ikertzaileekin lankidetzan egindako argitalpenak (61)

2024

  1. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future Oncology, Vol. 20, Núm. 13, pp. 799-809

  2. Applying design of experiments to optimize the performance level of a curling sport team

    TQM Journal, Vol. 36, Núm. 2, pp. 478-498

  3. Cardiovascular risk in young people with childhood onset systemic lupus erythematosus

    The Lancet Rheumatology

  4. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Clinical Therapeutics, Vol. 46, Núm. 8, pp. 612-621

  5. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

    The Journal of clinical investigation, Vol. 134, Núm. 3

  6. Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012

    Gynecologic Oncology, Vol. 189, pp. 68-74

  7. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer–a plain language summary

    Future Oncology, Vol. 20, Núm. 22, pp. 1531-1544

2023

  1. Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation Sparing Approaches: An International Cohort Study

    Journal of Clinical Oncology, Vol. 41, Núm. 10, pp. 1921-1932

  2. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

    Leukemia Research, Vol. 134

  3. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

    European Journal of Cancer, Vol. 189

2022

  1. Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors

    Pediatric Blood and Cancer, Vol. 69, Núm. 1

  2. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. Evaluation of the pediatric neuro-oncology resources available in Chile

    JCO Global Oncology, Vol. 7, pp. 425-434

  2. Follow-up evaluation of a web-based pediatric brain tumor board in Latin America

    Pediatric Blood and Cancer, Vol. 68, Núm. 9

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Cancer cell trapping and migration in a microfluidic device for anti-migration drug screening

    21st International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2017

  2. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma

    JAMA Oncology, Vol. 6, Núm. 5, pp. 724-734

  3. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

  4. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

    Gynecologic Oncology, Vol. 157, Núm. 2, pp. 379-385

  5. The influence of hip heat-treatments on the tensile and HCF properties of Ti6Al4V

    Euro PM 2018 Congress and Exhibition